EVALUATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) IN INTERDENTICULAR BONE MARROW IN OLPADRONATE TREATED ANIMALS

María M. Pujadas Bigi, Natalia D. Escudero, Ángela M. Ubios, Patricia M. Mandalunis

Department of Histology and Embryology, Faculty of Dentistry, University of Buenos Aires, Argentina.

ABSTRACT
Vascular endothelial growth factor (VEGF) is a protein that increases vascular permeability and induces the proliferation, migration and survival of endothelial cells. Bisphosphonates (BPs) are antiresorptive drugs that are widely used in the treatment of bone metabolism diseases and bone metastases. Since 2003, cases of bisphosphonate-related osteonecrosis of the jaw (BRONJ) have been reported. Few papers explain the mechanisms that induce BRONJ: some authors mention alterations in bone remodelling and a certain antiangiogenic effect of BPs. The aim of this study is to evaluate the expression of VEGF in bone marrow cells and the number of blood vessels and area occupied by them in animals treated with the BP sodium olpadronate (OPD).

We used 16 Wistar rats, 60 days old, divided into two groups, experimental (OPD) and control. The OPD group received 0.3 mg/kg/week intraperitoneal OPD for 5 weeks. The control group received an equivalent intraperitoneal volume of physiological saline solution. After euthanasia, hemimandibles were processed and mesio-distal histological sections of the first molar were prepared. Sections were stained with hematoxylin-eosin (HE), and mesio-distal histological sections of the first molar were prepared. Sections were stained with hematoxylin-eosin (HE), and mesio-distal histological sections of the first molar were prepared. Sections were stained with hematoxylin-eosin (HE), and mesio-distal histological sections of the first molar were prepared.

Further studies are needed to reveal its potential as an antitumor agent and its connection with the onset of BRONJ.

Key words: VEGF, bone marrow, blood vessels, anti-angiogenic agent.

EVALUACIÓN DEL VEGF EN LA MEDULA ÓSEA DEL HUESO INTERDENTICULAR EN ANIMALES TRATADOS CON OLPADRONATO

RESUMEN
El factor de crecimiento vascular (VEGF) es una proteína que incrementa la permeabilidad vascular, induce la proliferación, migración y supervivencia de las células endoteliales. Los bisfosfonatos (BFs) son drogas antiresorptivas ampliamente utilizadas en el tratamiento de enfermedades que alteran el metabolismo óseo y de metastasis óseas. Desde el 2003 se han reportado casos de osteonecrosis de maxilar asociada al uso de BFs (ONAB). Escasas publicaciones explican los mecanismos que inducen la ONAB, algunos autores mencionan las alteraciones en la remodelación ósea y un cierto efecto antiangiogénico de los BFs. El objetivo del presente trabajo es evaluar la expresión de VEGF en células de la médula ósea y el número y el área ocupada por vasos sanguíneos en animales tratados con el BF olpadronato monosódico (OPD).

Se utilizaron 16 ratas Wistar, 60 días de edad, divididas en dos grupos, experimental (OPD) y control. El OPD grupo recibió 0.3 mg/kg/semana de OPD vía IP, durante 5 semanas. El grupo control recibió un volumen equivalente vía IP de solución fisiológica. Luego de practicada la eutanasia se obtuvieron las hemimandibles e histomorfométricas. En cortes con H&E: Número de vasos sanguíneos/mm² y porcentaje (%) de área ocupada por los vasos sanguíneos en relación al área total evaluada; en cortes con immunohistoquímica de VEGF: Número de células medulares VEGF+/mm². Los datos fueron estadísticamente analizados.

Los resultados de este estudio sugieren que el olpadronato monosódico tiene un efecto antiangiogénico. Futuros estudios revelarán su potencial como agente antitumoral así como también su relación con la aparición de ONAB.

Palabras clave: VEGF, medula ósea, vasos sanguíneos, agente antiangiogénico.

INTRODUCTION
Vascular endothelial growth factor (VEGF) was first isolated simultaneously by Ferrara and Henzel, and Ploüet et al., who published the purification of an NH₂-terminal amino acid sequence of a mitogen specific for endothelial cells, which they called, respectively, vascular endothelial growth factor (VEGF) and vasculotropin (VPF). It was subse-
quentely shown that the activity of both factors corresponded to the same molecule. The discovery that VEGF was powerful, specific and freely diffusible for vascular endothelial cells led to the hypothesis that it played a unique part in regulating physiological and pathological angiogenesis. VEGF is a mitogen that is specific for endothelial cells and has no mitogenic activity on any other kind of cell. In three-dimensional in vitro models it promotes angiogenesis by inducing the formation of capillary-like structures in a collagen gel, and in in vivo models it induces a strong angiogenic response. In endothelial cell cultures it works as a survival factor, and both in vivo and in vitro, it induces the appearance of fenestrations in the vascular endothelium.

Bisphosphonates are analogues of pyrophosphates, in which the linking oxygen is replaced by a carbon atom with different side chains. They were used industrially in the early 19th century as anti-scaling and anticorrosive agents. It was later discovered that they could control the dissolution of calcium and phosphate in vitro, as well as bone mineralization and resorption in vivo. Later on, these drugs were developed for the treatment of various diseases that alter bone metabolism, such as osteoporosis, Paget’s disease, hypercalcaemia of malignancy and bone metastases. They may be administered orally or intravenously, and their potency varies according to whether or not they are nitrogenated and according to the side-chains they contain. For about the last decade, BPs (particularly pamidronate and zoledronic acid) have been used as therapeutic agents for bone metastases of prostate cancer. They reduce the symptoms and bone complications because they inhibit the osteoclast activity that leads to bone destruction. Current pre-clinical trials have shown that BPs can also reduce visceral metastases; however, the anti-tumor action mechanism on non-bone metastases is as yet unknown.

As of 2003, reports have been published on patients with bisphosphonate-related osteonecrosis of the jaw (BRONJ), related to either intravenous IV or oral administration of bisphosphonates. Some authors assign the onset of BRONJ to the effect of BPs on bone metabolism, bone marrow cells and an antiangiogenic effect. However, the studies showing association between the onset of BRONJ and the antiangiogenic effect of BPs are few and controversial. Olpadronate (OPD) is a monosodium amino-bisphosphonate of similar potency to alendronate, with excellent gastric tolerance thanks to its double methylation. Although many studies describe the anti-resorption effect of OPD, there is no study describing an antiangiogenic effect nor its anti-tumor capacity or its association with BRONJ.

The aim of this study is to assess the antiangiogenic effect of OPD by evaluating the expression of VEGF and the number and surface area of blood vessels in the bone marrow of the interradicular bone of the first lower molar.

**MATERIALS AND METHODS**

Sixteen Wistar rats 60 days old were divided into two groups: experimental (OPD) and control (C). The OPD group received 0.3 mg/kg/week OPD intraperitoneally (IP) for five weeks, and the sh group received an equivalent volume of physiological saline solution, IP. The rats were euthanized in the sixth week after the beginning of the experiment. They were sedated with 0.5 mg/kg acepromazine after which they were given a lethal overdose of sodium thiopental (Pentotet®, Richmond Vet, Buenos Aires, AR). The hemimandibles were resected and fixed in 10% PBS formalin buffer. Then they were de-calcified in 10% EDTA (ethylene diamine tetraacetic acid) and processed for embedding in paraffin. Histological sections were made of the first lower molar, oriented mesio-distally. Two sections were made per experimental unit: one for H&E staining and the other for immunohistochemical detection of VEGF. Digital photographs were taken of all sections with an original magnification of 400X, using Image Pro Plus 4.0 software. Histomorphometric evaluation was performed on a standardized area of the interradicular bone. The area was standardized in the most apical third of the interradicular bone of the first lower molar (Fig. 1). The following histomor-
phometric parameters were evaluated in the bone marrow: a) in the sections stained with H&E: number of blood vessels per square millimeter (n° blood vessels/mm²) and percentage of area occupied by blood vessels compared to total area evaluated (% vascular area/total area); b) in the sections with immunohistochemical detection of VEGF, the number of VEGF+ marrow cells per square millimeter (n° VEGF+ cells/mm²) was evaluated. Statistical analysis was performed with Student’s T test. All procedures were reviewed and approved by the Ethics Committee of the School of Dentistry, which follows the Guide for the Care and Use of Laboratory Animals (NRC 1996).

RESULTS

The densitometry of the apical third of the interradicular bone indicated 20% trabeculae and 80% bone marrow in both the experimental group and the control group. The number of blood vessels per square millimeter was significantly lower in the OPD group; OPD: 92 ± 16, C: 140 ± 31; p<0.05 (Fig. 2), while the percentage of area occupied by blood vessels showed no significant difference between groups; OPD: 15.6 ± 6.1; C: 10.2 ± 4.2 (Fig. 3). Images are provided in Figures 4a (control) and 4b (OPD). The number of VEGF+ cells per square millimeter in the OPD group was significantly lower than in the control group; OPD: 7804.8 ± 597; control: 13187.6 ± 894; p<0.001 (Fig. 5).

Fig. 2: Graph showing number of blood vessels/mm². Note that it is significantly lower in the OPD group than in the control group (p<0.05).

Fig. 3: Graph showing percentage of area occupied by blood vessels in the groups studied. The difference was not statistically significant.

Fig. 4a: Microphotographs of sections stained with H&E, where the border of the blood vessels has been marked. a: control.

Fig. 4b: OPD. The number of vessels is lower and the area occupied by the vessels is greater in the OPD group than in the control group.
DISCUSSION
The results of this study showed that olpadronate bisphosphonate administered intraperitoneally reduced the number of blood vessels/mm² compared to the control group, while no difference was found in the percentage of area occupied by blood vessels between the experimental group and the control group.

The number of VEGF+ marrow cells was significantly lower in the experimental group than in the control group. The fact that there were fewer blood vessels, while at the same time there was no significant difference in the area occupied by the blood vessels between groups, might be a functional adaptation of vascularization to tissue requirements by means of an increase in the vascular area in experimental animals. The reduction of VEGF+ cells suggests an antiangiogenic effect of olpadronate, not described to date in the literature.

Although several papers have described the antitumor action of certain bisphosphonates, there is still controversy regarding the existence of an antiangiogenic action mediated by a reduction in VEGF. The antitumor action of powerful bisphosphonates such as zoledronic acid and minodronic acid (YM529) is related to the prevention of proliferation and induction of apoptosis, and they are believed to act synergically with chemotherapeutic agents; yet none of these reports mention changes in the expression of VEGF.

In a clinical study conducted by Amir et al. 2009 on patients medicated with zoledronic acid, the concentration of VEGF was measured in platelets, showing no significant change compared to patients who did not undergo this treatment; whereas Lippton, in the same year, performed a clinical study on patients with bone metastases who were under treatment with the BP zoledronic acid, and found that basal levels of VEGF were significantly reduced, suggesting that zoledronic acid might have clinically relevant antiangiogenic properties. Hashimoto et al. 2007 report that alendronate has an antiangiogenic effect by inhibiting the generylgeranylation of Rho without altering the expression of VEGF.

The study of the antiangiogenic effect of bisphosphonates began to increase in relevance in 2003, when bisphosphonate-associated osteonecrosis of the jaws (BRONJ) was reported and partly attributed to the effect of BPs on angiogenesis, bone remodeling and bone marrow cells. Despite the fact that many papers have been published, the antitumor and physiopathology of BRONJ is still under study. The antiangiogenic action produced by BPs in the bone marrow of animals free of disease, plus the inhibitory action on bone metabolism, particularly at the expense of bone resorption, may partly explain the physiopathology of BRONJ and the antitumor effect of these drugs.

CONCLUSION
The results of this study suggest that monosodium olpadronate has an antiangiogenic effect. As it is a relatively new bisphosphonate that is still under study, further research is needed to reveal its potential as an antitumor agent and its connection to the onset of BRONJ.

ACKNOWLEDGEMENTS
Grants: UBACyT O 018 and UBACYT O 406, University of Buenos Aires. The authors want to express their gratitude to Mariela Lacave, Carolina Acuña and Vet Maríanel Lewicki and Carolina Roman for their technical assistance.

CORRESPONDENCE
Dra. María Montserrat Pujadas Bigi
Department of Histology and Embryology
M.T. de Alvear 2142, 1º “A”
C1122AAH Ciudad Autónoma de Buenos Aires
Argentina
E-mail: montsepujadas@gmail.com
REFERENCES